The diagnostics firm reported Q1 2026 revenue above expectations and raised full-year guidance, signaling stronger demand.
Castle Biosciences reported Q1 2026 revenue of $52.3 million, surpassing the $48.5 million consensus estimate. The beat was driven by higher-than-anticipated test volumes and pricing adjustments in its dermatological portfolio.
Analysts had expected revenue growth of 12% year-over-year, but the company delivered 18%, matching its performance in Q4 2025. The prior quarter’s revenue stood at $49.7 million, with guidance initially set at $200 million for 2026.
The company raised its full-year revenue guidance to a range of $215–$220 million, citing sustained demand and operational efficiencies. Shares rose 4.2% in after-hours trading following the announcement.